Who is good for the lifting of the ban on online sales of prescription drugs?
Ordinary online pharmacy business operators have almost no other choice but to join the Internet platform. In addition to paying traffic fees to the platform, they also have to pay electronic prescriptions and other fees. Not long ago, at the "West Lake Forum" held in Wuzhen, some practitioners complained: "I thought that doing O2O could get new increments, but when I actually did it, I found that online sales increased while offline sales decreased." Between this "one rise and one drop", there is a lot of expenditure for no reason, such as distribution fees, platform points, and so on. Specific landing policy is not introduced, objectively or will compress the space of small and medium-sized operators.
For Internet medicine platforms, since the ''Internet Food and Drug Operation Supervision and Administration Measures (Draft for Comment) ''released in 2014 first mentioned that the liberalization of online prescription drugs has triggered the development of the industry, favorable policies have been released, unless there is a big breakthrough in Internet medical insurance settlement. For the time being, the Internet medicine platform has no more policy" dividends "to enjoy. The benefits of the taste have been tasted and the investment that should be made has been made. With the introduction of specific landing policies in the future, the continuous promotion of anti-monopoly and the clarity of regulatory policies, the advantages of platform enterprises alone from the policy point of view may have reached the top.
Evolving a new competitive ecology
The "opinions on the release of management and service" part of the specific landing policy requirements, clear electronic prescription source is true and reliable is the network sales of prescription drugs pre-condition, which also means that the network sales of prescription drugs landing policy at least partially clear, some for pharmacies to provide electronic prescription services as the main business of the company will usher in development opportunities. These companies will be more willing to focus on building an electronic prescription platform, and it will be easier to obtain capital favor, get funds, and promote the large-scale development of electronic prescription platforms.
These enterprises will evolve a new competitive ecology together with pharmaceutical chain enterprises, especially small and medium-sized chain pharmacies.
For small and medium-sized pharmacies, the commission paid to the platform can be exempted, which ranges from 5 points to more than 10 points, seriously squeezing the already weak profit margin of pharmacies. For medium and large chain pharmacies, in addition to cooperating with third-party prescription platforms, they can also build self-operated B2C or O2O platforms through self-built electronic prescription service platforms. For large and medium-sized chains that already have huge offline traffic, it is more in line with their long-term interests to build a "medicine" private domain traffic ecology, rather than relying solely on the Internet pharmaceutical platform. Driven by these new forces, the future online prescription drug market will be more diversified, rather than showing the dominance of Internet giants.
For the majority of small and medium-sized chain drugstore enterprises, instead of worrying about changes in the industry, it is better to take practical actions, consolidate internal management, reduce operating costs, carefully study user needs, constantly adjust services, and do detailed work to attract and retain users; pay attention to external changes in the industry, boldly run pilot projects in small steps, and adjust flexibly. Such enterprises, no matter what kind of environment, will have its unique value.